Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.
about
High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphomaHigh-dose chemotherapy followed by autologous stem cell transplantation for refractory/relapsed Hodgkin lymphoma patientsAdvances in the treatment of relapsed or refractory Hodgkin's lymphomaPembrolizumab in classical Hodgkin's lymphomaHodgkin lymphoma, version 2.2015.Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma.Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients.GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma.Metastatic Angiosarcoma with Kasabach-Merritt Syndrome Responsive to Gemcitabine and Vinorelbine after Failure of Liposomal Doxorubicin and Paclitaxel: A Case Report.High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignanciesEmerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategiesPhase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphomaSerious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.Hodgkin's lymphoma therapy: past, present, and future.Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology ConsortiumDoxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PETThe Management of Classical Hodgkin's Lymphoma: Past, Present, and FuturePhase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.A case of Hodgkin's lymphoma with severely impaired liver function treated successfully with gemcitabine followed by ABVDGemcitabine, navelbine, and doxorubicin as treatment for patients with refractory or relapsed T-cell lymphomaManagement of fertility in patients treated for Hodgkin's lymphoma.Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab VedotinCurrent status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphomaTreatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation.Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphomaRelapsed Hodgkin lymphoma: management strategiesCurrent role of gemcitabine in the treatment of Hodgkin lymphoma.Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience.Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma.High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging.The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type.
P2860
Q24201885-C38CF2C1-97FE-4085-8856-4D3F00351FAFQ24235563-6664A872-82F3-47DF-9BE1-654065425FB5Q27694504-A3D9AD5E-54AF-4434-A8A9-18CA7B28D78CQ28079273-C219F173-5455-4120-A43B-901890592F03Q30769157-A643919D-677C-444C-BAC3-7B807A2175EAQ33404875-7A83A758-E6AE-4CB9-AC0E-44ADF1E63C94Q33405357-FFD13031-E173-47EB-BDFB-A10EAB51E88BQ33405891-F718E6BC-C222-4BD7-B89C-ABC0C88534CAQ33411127-8B463F13-142D-49A3-AB5D-396675E2884CQ33418817-A156EBD3-2DDF-49E1-8FCB-82F999B5BAD6Q33431410-4B2A7A08-1285-480A-825D-E175C6982B31Q33566475-3B564176-B3BE-4E8B-8E2B-DE16CE8B8199Q33704061-84B23CCC-BE6B-4351-8675-7A2766850DADQ33828956-B00EDD13-B8A9-43E6-9606-A4DE4B82B9FFQ33886267-0FC32E7B-ECD2-4A86-AA83-22C3DE044D05Q34064220-9FAFEC81-5641-448D-A329-DF3201E7DBBCQ34231085-2DDB4BEF-17E2-42AD-B7F2-96FF8CB57769Q34240314-B9F42178-CD8A-4697-BFE4-BE0DF8F92C7BQ34296914-6A79B070-C431-4B87-84AA-4AE2EF80EC82Q34477705-9E95ABBE-1217-4914-B9CF-F66938AD160AQ35029924-6CC2274E-B8A2-49DE-85E0-4860E3B6C062Q35038852-7597561B-E67D-466B-ABB7-C0614E176BDAQ35051886-516D6986-D6E2-4D2F-9DBC-DD42A691EBF0Q35223515-0A7C28AE-E1AD-449B-9722-18CD6D154A37Q35249315-CF235F17-FE5C-48E0-9AA5-621AD2A37654Q35528686-12058A47-9749-41DC-B9F3-11F67F56192CQ35669134-D91AA5B1-7EA0-4E17-BE52-46A3DEF47A5FQ35705317-E06AA60F-D33B-4A70-BE19-610F7ACAB363Q35865599-87A5DC9A-FC68-45E9-ACFC-885ED23CBDC0Q36182830-0721A16D-8BFD-437B-9370-868299598092Q36264723-9A5B01E4-6082-4940-9A79-82A97F09E553Q36822162-276B2CE9-170C-482B-B178-D4A75E44B85BQ37008427-33BD9535-E9A0-412D-9734-A9EA384B02F4Q37152761-014A0206-38EF-4710-B195-93134623CB73Q37216194-1643F323-2556-4983-BAD3-9120AF74D634Q37238152-DC1CA6FC-5F46-4375-8544-2412F6F06B0CQ37326210-DA094AAF-4518-4EF5-882C-38B5C715CBFEQ37530611-8DD42E49-35A5-4479-8794-F867440FEB24Q37577385-5A9323D3-C750-4045-8741-E3BDE662FBC1Q37629033-48ED8D7D-F9C1-497E-A70A-4CE4589BC58D
P2860
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Gemcitabine, vinorelbine, and ...... dgkin's lymphoma: CALGB 59804.
@ast
Gemcitabine, vinorelbine, and ...... dgkin's lymphoma: CALGB 59804.
@en
type
label
Gemcitabine, vinorelbine, and ...... dgkin's lymphoma: CALGB 59804.
@ast
Gemcitabine, vinorelbine, and ...... dgkin's lymphoma: CALGB 59804.
@en
prefLabel
Gemcitabine, vinorelbine, and ...... dgkin's lymphoma: CALGB 59804.
@ast
Gemcitabine, vinorelbine, and ...... dgkin's lymphoma: CALGB 59804.
@en
P2093
P356
P1433
P1476
Gemcitabine, vinorelbine, and ...... odgkin's lymphoma: CALGB 59804
@en
P2093
A D Zelenetz
B D Cheson
Cancer Leukemia Group B
D Niedzwiecki
G P Canellos
J L Johnson
J W Friedberg
K B Johnson
P304
P356
10.1093/ANNONC/MDM090
P577
2007-04-10T00:00:00Z